{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:18:12Z","timestamp":1773080292942,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"DOI":"10.7759\/cureus.97311","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:07:02Z","timestamp":1763640422000},"source":"Crossref","is-referenced-by-count":1,"title":["Atezolizumab and Bevacizumab Induced Diabetes Mellitus and Myocarditis: A Case Report"],"prefix":"10.7759","author":[{"given":"Muhammad A","family":"Mirza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vimalraj","family":"Periyasami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amail","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthana","family":"Pampapathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyanarayana V","family":"Sagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1919-8494","article-title":"Immunotherapy in hepatogastroenterology - update 2022: efficacy and immune-related adverse events [Article in German]","volume":"148","author":"Krimmel L","year":"2023","unstructured":"Krimmel L, Quante M, Bengsch B. Immunotherapy in hepatogastroenterology - update 2022: efficacy and immune-related adverse events [Article in German]. Dtsch Med Wochenschr. 2023, 148:294-300. 10.1055\/a-1919-8494","journal-title":"Dtsch Med Wochenschr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15935","article-title":"Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: a multicentre, retrospective study","volume":"44","author":"Cheon J","year":"2024","unstructured":"Cheon J, Jung S, Kim JS, et al.. Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: a multicentre, retrospective study. Liver Int. 2024, 44:1961-70. 10.1111\/liv.15935","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237217","article-title":"Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions","volume":"14","author":"Oldfield K","year":"2021","unstructured":"Oldfield K, Jayasinghe R, Niranjan S, Chadha S. Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions. BMJ Case Rep. 2021, 14:10.1136\/bcr-2020-237217","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2203-3","article-title":"Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC","volume":"67","author":"Matsuura N","year":"2018","unstructured":"Matsuura N, Koh G, Konishi C, et al.. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC. Cancer Immunol Immunother. 2018, 67:1417-24. 10.1007\/s00262-018-2203-3","journal-title":"Cancer Immunol Immunother"},{"key":"ref6","unstructured":"The Clatterbridge Cencer Centre. Immunotherapy guidance. (2025). Accessed: November 19, 2025: https:\/\/www.clatterbridgecc.nhs.uk\/professionals\/clinical-guidance\/immunotherapy-guidance."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810948","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"23","author":"Cozma A","year":"2022","unstructured":"Cozma A, Sporis ND, Lazar AL, et al.. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Int J Mol Sci. 2022, 23:10948. 10.3390\/ijms231810948","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1290","article-title":"Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics\u00a0and future treatment strategies","volume":"17","author":"Liu X","year":"2021","unstructured":"Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics\u00a0and future treatment strategies. Future Oncol. 2021, 17:2243-56. 10.2217\/fon-2020-1290","journal-title":"Future Oncol"},{"key":"ref9","article-title":"Atezolizumab and bevacizumab combination therapy for hepatocellular carcinoma","volume":"16","author":"El-Khoueiry A","year":"2020","unstructured":"El-Khoueiry A. Atezolizumab and bevacizumab combination therapy for hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2020, 16:145-8.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026377","article-title":"Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: case report and literature review","volume":"100","author":"\u00d6zdirik B","year":"2021","unstructured":"\u00d6zdirik B, Jost-Brinkmann F, Savic LJ, et al.. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: case report and literature review. Medicine (Baltimore). 2021, 100:e26377. 10.1097\/MD.0000000000026377","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez E","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016, 21:804-16. 10.1634\/theoncologist.2015-0509","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2110","article-title":"A case of biopsy-proven acute interstitial nephritis following atezolizumab-bevacizumab treatment of advanced unresectable hepatocellular carcinoma","volume":"7","author":"Patel R","year":"2024","unstructured":"Patel R, Elghawy O, Gibbs A, Gupta S, Kaur V. A case of biopsy-proven acute interstitial nephritis following atezolizumab-bevacizumab treatment of advanced unresectable hepatocellular carcinoma. Cancer Rep (Hoboken). 2024, 7:e2110. 10.1002\/cnr2.2110","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.940688","article-title":"Corneal perforation in a patient treated with atezolizumab-bevacizumab combination therapy for unresectable hepatocellular carcinoma","volume":"24","author":"Alkharashi MS","year":"2023","unstructured":"Alkharashi MS, Al-Essa RS, Otaif W, Algorashi I. Corneal perforation in a patient treated with atezolizumab-bevacizumab combination therapy for unresectable hepatocellular carcinoma. Am J Case Rep. 2023, 24:e940688. 10.12659\/AJCR.940688","journal-title":"Am J Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari MJ","year":"2003","unstructured":"Ansari MJ, Salama AD, Chitnis T, et al.. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003, 198:63-9. 10.1084\/jem.20022125","journal-title":"J Exp Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2009.04.006","article-title":"Altered availability of PD-1\/PD ligands is associated with the failure to control autoimmunity in NOD mice","volume":"258","author":"Yadav D","year":"2009","unstructured":"Yadav D, Hill N, Yagita H, Azuma M, Sarvetnick N. Altered availability of PD-1\/PD ligands is associated with the failure to control autoimmunity in NOD mice. Cell Immunol. 2009, 258:161-71. 10.1016\/j.cellimm.2009.04.006","journal-title":"Cell Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0860-22","article-title":"Development of fulminant type 1 diabetes mellitus in the course of treatment with atezolizumab for hepatocellular carcinoma","volume":"62","author":"Ikeda M","year":"2023","unstructured":"Ikeda M, Tamada T, Takebayashi R, et al.. Development of fulminant type 1 diabetes mellitus in the course of treatment with atezolizumab for hepatocellular carcinoma. Intern Med. 2023, 62:1775-9. 10.2169\/internalmedicine.0860-22","journal-title":"Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem JE","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018, 19:1579-89. 10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi J","year":"2021","unstructured":"Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest. 2021, 131:10.1172\/JCI145186","journal-title":"J Clin Invest"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline","volume":"38","author":"Gordan JD","year":"2020","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, et al.. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020, 38:4317-45. 10.1200\/JCO.20.02672","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426401-atezolizumab-and-bevacizumab-induced-diabetes-mellitus-and-myocarditis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:07:05Z","timestamp":1763640425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426401-atezolizumab-and-bevacizumab-induced-diabetes-mellitus-and-myocarditis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.97311","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}